Arizona Hepatitis C Free Data Subcommittee. Meeting held on May 4, 2021. Two of the authors of this paper attended this meeting and are on the subcommittee.
Arizona SB1250. [online]: https://apps.azleg.gov/BillStatus/BillOverview/75001 Accessed July 9, 2021.
Arizona State Department of Health Services. 2016 Viral Hepatitis Epidemiologic Profile for Arizona. [online]: https://www.azdhs.gov/documents/preparedness/epidemiology-disease-control/hepatitis/arizona-2016-viral-hepatitis-profile.pdf Accessed October 8, 2021.
Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, Palmateer N, Doyle JS, Hellard ME,Hutchinson SJ (2014). Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. International Journal of Epidemiology, 43(1): 235-248.
Baumgartner JC, Radley DC (2021). The spike in drug overdose deaths during the COVID-19 pandemic and policy options to move forward. Commonwealth Fund, March 25, 2021. [online]: https://www.commonwealthfund.org/blog/2021/spike-drug-overdose-deaths-during-covid-19-pandemic-and-policy-options-move-forward Accessed July 2, 2021.
Centers for Disease Control and Prevention (2021). Hepatitis C tables and figures. [online]: https://www.cdc.gov/hepatitis/statistics/2017surveillance/TablesFigures-HepC.htm#tabs-1-1 accessed March 23, 2021.
City of Phoenix. Phoenix Facts. [online]: https://www.phoenix.gov/pio/facts Accessed December 16, 2021.
Drobnik, Ann, et al (2011). "Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations." American Journal of Public Health, 101(11): 2151-2155.
Fernandes RM, Cary M, Duarte C, Jesus C, Alarc o J, Torre C, Costa S, Costa J, Vaz Carneiro A (2017). Effectivness of needle and syringe programmes in people who inject drugs- an overview of systematic reviews. BMC Pub Health, 17:309-26. https://doi.org/10.1186/s12889-017-4210-2
Gamkrelidz I, Pawlotsky J-M, Lazarus JV, Feld JJ, Zuezum S, Bao Y, Pires dos Santos AG, Gonzales YS, Razavi H (2021). Progress toward hepatitis C virus elimination in high-income countries: An updated analysis. Liver International, January. [online]: https://doi.org/10.1111/liv.14779
Gonsalves GS, Crawford FW (2018). Dynamics of the HIV outbreak and response in Scott County, IN, USA, 2011-2015: a modeling study. Lancet HIV, 5:e569-577.
Gordon SC (2018). Hepatitis C virus detection and treatment in rural communities. Gastroenterol Hepatol, 14(2):720-722.
Ha A, Timmerman K (2018). Awareness and knowledge of hepatitis C among healthcare providers and the public: A scoping review. Can Commun Disp Rep., 44(7-8):157-165.
Hoenigl, Martin, Joshua Graff-Zivin, and Susan J. Little (2016). "Costs per diagnosis of acute HIV infection in community-based screening strategies: a comparative analysis of four screening algorithms." Clinical Infectious Diseases, 62.4: 501-511.
Hofmeister MG, Rosenthal EM, Barker LK, et al (2019). Estimating prevalence of hepatitis C virus infection in the United States, 2013‐2016. Hepatology, 69:1020‐1031.
Kaufman HW, Bull-Otterson L, Meyer WA, Huang X, Doshani M, et al (2021). Decreases in hepatitis C testing and treatment during the COVID-19 pandemic. Am J Prev Med, [online]: https://doi.org/10.1016/j.amepre.2021.03.011 Accessed July 2, 2021.
Latham NH, Pedrana A, Doyle JS, Howell J, Williams B, Higgs P, Thompson AJ, Hellard ME (2019). Community-based, point of care hepatitis C testing: perspectives and preferences of people who inject drugs. J Viral Hep, 26(7):919-922.
Meyerson BE, Davis A, Agley JD, Shannon DJ, Lawrence CA, Ryder PT, Ritchie K, Gassman R (2018). Predicting pharmacy syringe sales to people who inject drugs: Policy practice and perceptions. Int J Drug Policy, 56:46-53.
Meyerson BE, Lawrence CA, Cope SD, Levin S, Thomas C, Eldridge LA, Coles HB, Vadiei N, Kennedy A (2019). I could take the judgement if you could just provide the service: non-prescription syringe purchase experience in Arizona pharmacies. BMC Harm Reduction, 16(57):1-9.
Meyerson BE, Russell DM, Kichler M, Atkin T, Fox G, Coles HB (2021). I don't even want to go to the doctor when I get sick now: Healthcare experiences and discrimination reported by People who Use Drugs, Arizona 2019. Int J Drug Pol. https://doi.org/10.1016/j.drugpo.2021.103112
Millman AJ, Nitri-Reid B, Irvin R, Kaufmann MH, Aronsohn A, Duchin JS, Scott JD, Velozzi C (2017). Barriers to treatment access for chronic hepatitis C virus infection: A case series. Top Antivir Med, 25(3):110-113.
North American Syringe Exchange Network. SEP Locations. [online]: https://www.nasen.org/map/ Accessed August 6, 2019.
Office of Governor Doug Ducey. FY22 Budget: Tax Relief #ForArizonans. [online]: https://azgovernor.gov/FY22budget Accessed December 16, 2021.
Platt L, Minozzi S, Reed J, Vickerman P, Hagen H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer L, Palmateer N, Taylor A, Bruneau J, Hickman M (2017). Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev, (9):CD01201.
Private author correspondence, 2021. This information was shared with the Arizona hepatitis C free advisory group in 2021. Two authors of this paper (KB and BM) are members.
Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB (2020). CDC Recommendations for Hepatitis C Screening Among Adults — United States, 2020. MMWR Recomm Rep, 69(No. RR-2):1–17. DOI: http://dx.doi.org/10.15585/mmwr.rr6902a1external icon.
Simões D, Steingaard AR, Combs L, Raben D, et al. (2020). Impact of the COVID-19 pandemic on testing services for HIV, viral hepatitis and sexually transmitted infections in the WHO European region, March to August 2020. Euro Surveillance, 25(47):2001943.
Strathdee SA, Patrick DM, Currie SL, Cornelisse PG, Rekart ML, Montaner JS, Schechter MT, O’Shaughnessey MV (1997). Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS, 11:F59-F65.
Thomas DL. State of the hepatitis C virus care cascade (2019). Clin Liver Dis, 16(11):8-11.
Tohme RA, Xing J, Liao Y, Holmberg SD (2013). Hepatitis C testing, infection and linkage to care among racial and ethnic minorities in the United States, 2009-2010. Am J Pub Health, 103(1):112-119.
Trooskin, Stacey B., et al (2015). "Results from a geographically focused, community-based HCV screening, linkage-to-care and patient navigation program." J Gen Intern Med, 30(7): 950-957.
Trust for America’s Health (2019). Investing in America’s health: A state-by state look at public health funding and key facts. (Washington, DC), April 2016. [online]: https://www.tfah.org/reportdetails/investing-in-americas-health-a-state-by-state-look-at-public-health-funding-and-keyhealth-facts-1/ Accessed April 16, 2019.
United States Census. QuickFacts: Maricopa County, Arizona. [online]: https://www.census.gov/quickfacts/maricopacountyarizona Accessed October 4, 2021.
United States Health and Human Services. Mapping hepatitis elimination in action (2021). [online]: https://www.hhs.gov/hepatitis/mapping-hepatitis-elimination-in-action/index.html accessed July 2 2021.
Van Handel MM, Rose CE, Hallisey EJ, et. Al (2016). County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States. J Acquir Immune Defic Syndr, Nov 1;73(3): 323-331.